Speakers

  • Frank McCormick, PhD
    Professor of the UCSF Helen Diller Family Comprehensive Cancer Center
    Biography
      Frank McCormick, PhD, FRS, is Professor of the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick's group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies. Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.
    • Mark Hellewell, PhD
      DISCOVERY Reagent & Training Lead, Companion Diagnostics (CDx) & DISCOVERY, Roche Tissue Diagnostics
      Biography
        Mr. Hellewell has been with Roche Tissue Diagnostics (RTD) for 8 years where he has held several positions within the company. He began his career with RTD UK where he held sales and applications positions. In 2016 he relocated to Tucson, AZ to take up a global role with customer support for RTD. In 2107 he joined the DISCOVERY International Business team as Global Reagent and Training Lead, where he manages their reagent portfolio and global DISCOVERY training activities for customers and RTD personnel.
      • Christopher Bunker, PhD
        Vice President of Business Development, Advanced Cell Diagnostics
        Biography
          Dr. Christopher Bunker is the Vice President of Business Development at Advanced Cell Diagnostics (ACD) in Newark, California. Dr. Bunker completed his doctoral research in Biological Chemistry at Harvard University and a Leukemia Society of America postdoctoral fellowship in molecular genetics at UCSF. He was a senior scientist in cancer functional genomics at Genome Therapeutics before joining Cell Signaling Technology at its inception in 2000. Dr. Bunker received an M.B.A from Boston University. He joined ACD in 2010, where he has led its assay services business for the past 8 years.
        • G. Thomas Caltagirone, PhD
          President & CEO, Aptagen, LLC
          Biography
            Dr. Caltagirone is the President & CEO of Aptagen and has over 25 years of research and business experience in start-ups. A native of York, PA, he began his studies at the University of the Sciences in Philadelphia followed by a Ph.D. in neuroscience from Drexel University. He completed his thesis on "Proton-Sensitive Ribozyme Switches with Molecular Memory" at Yale University, and has several patents and publications under his name.
          • Jay Campbell
            Chief Commercial Officer, Somark Innovations
            Biography
              Jay has spent the past 30 years as a commercial lead in marketing and sales for several of the top leading life science providers including Corning Life Sciences and Charles River Laboratories. He recently joined Somark Innovations as Chief Commercial Officer where he is responsible for the global sales and marketing organization as well as supporting all new technology launches. He is an advocate for better science and science processes as he ultimately believes these will bring about cures faster.
            • Maude Champagne
              Clinical Oncology Marketing, Illumina, Inc.
              Biography
                Maude is a specialist in molecular biology applications in oncology, across technologies and platforms. Her experience includes contributing to the FDA-approval of 5 Companion Diagnostic (CDx) molecular assays, creating the global go-to-market strategy for a dozen of CDx at various stages in regulatory approval. Maude has educated pathologists and oncologists in early adoption of technologies that have changed medicine and cancer treatments in the last decade.
              • Richard Eglen, PhD
                Vice President and General Manager, Corning Life Sciences
                Biography
                  Dr. Richard M. Eglen is Vice President and General Manager of Corning Life Sciences. Dr. Eglen has over 40 years' experience in the Life Sciences industry. Prior to joining Corning in 2011, he was president of Bio-discovery at PerkinElmer and held other executive management positions in the pharmaceutical, diagnostic, and biotech industries. Dr. Eglen has extensive experience in the use of cellular biology to study key drug targets, including GPCRs, kinases, and ion channels. He has also wide experience in assay and instrument technology development for high-throughput screening, imaging, and biomarker detection. He has authored over 350 publications, book chapters, and patents, and serves on numerous industry, academic advisory, and journal editorial boards.
                • Phillip Febbo, MD
                  Chief Medical Officer, Illumina, Inc.
                  Biography
                    For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.
                  • Matthew Flegal, BS, SRS
                    Senior Associate Scientist, Behavioral Pharmacology and Surgery, Biogen
                    Biography
                      Matt entered the research field over 24 years ago as a lab animal technician at the TSI/Mason contract research facility. Since then, he has worked at contract facilities such as TSI and OREAD Biosafety as well as in industry at Pharmacia, Pfizer, Sanofi-Aventis, and Biogen. During that period he has performed a variety of surgical procedures including device implantation, transplants, orthopedic defect, ocular and vascular implants, cardiac surgery, and brain and spinal procedures. His experience ranges from mice and rats to non-human primates and livestock. In addition, he holds four patents for novel surgical devices and implants and has been training technicians, scientists, veterinarians, and physicians in surgical techniques and procedures for over 18 years. Outside of the surgical realm, he has been a study director, sonographer, Safety Pharmacology scientist, and manager. Currently Matt supervises a team of associates at Biogen who conduct surgical and non-surgical studies. Matt was also on the board of directors for the Academy of Surgical Research for over ten years, serving as their program chair for three of them as well as educational chair for two. Currently he is the program chairman for the New England branch of AALAS.
                    • Bill Jackson, PhD
                      Founder and Chief Scientist, Base Pair Biotechnologies
                      Biography
                        Dr. Jackson has served as Principal Investigator on over $5M in Small Business Innovation and Research grants. Dr. Jackson is also a recognized leader in the aptamer space, having authored twelve peer-reviewed publications on aptamers as well as 50+ posters and conference proceedings. In 2010 he co-authored the first market research report on aptamers. Dr. Jackson is inventor on twelve issued U.S. patents (and many corresponding international filings) as well as numerous patents pending. Dr. Jackson holds a B.S. in biomedical engineering and a B.A. in Spanish literature from Texas A&M University and a Ph.D. in chemical engineering from the University of Houston.
                      • Adrian Kinkaid
                        CEO, MIP Diagnostics
                        Biography
                          Adrian Kinkaid is CEO of MIP Diagnostics (www.mip-dx.com ) which was founded in 2015 to commercialise nano-structured molecularly imprinted polymers, nanoMIPs or "plastic antibodies". Since joining Abcam in 2010, as Head of Technology Access, Adrian has worked with all the major forms of affinity reagents (antibodies, aptamers, affinity proteins and MIPs). Prior to this, he lead Drug Discovery teams at Lectus Therapeutics, Inpharmatica, Biofocus and Celltech Chiroscience (now UCB). He has a PhD in Biochemistry from Southampton and has twice served as Chairman of ELRIG: the European Laboratory Research & Innovation Group.
                        • Jagath Reddy Junutula, PhD
                          Senior Vice President, Research & Development, ModMab Therapeutics, Inc.
                          Biography
                            Over 15 years of experience in oncology drug discovery and development/antibody therapeutics and more than 20 years of experience in the life science research as a biochemist/molecular cell biologist. Recognized in the scientific and pharmaceutical communities for inventing and developing a novel and innovative THIOMAB technology platform to obtain engineered ADCs with defined number of payloads per conjugate. Authored over 100 patents/peer-reviewed publications and have been a featured keynote speaker at many international high-profile scientific conferences. Led cross-functional teams in the discovery of innovative Antibody Dug Conjugates (ADCs) and Bi-specific cancer immunotherapeutic programs. Core member of launched T-DM1 (Kadcyla) R&D team. Led the teams, which discovered and developed a next generation site-specific T-DM1 ADC project and over 10 other ADC/Bi-specific antibody therapeutic candidates. Leveraged several cross-functional teams in discovery research, pre-clinical research and manufacturing to move antibody based therapeutic molecules from discovery to IND.
                          • Shivaani Kummar, MD, FACP
                            Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford), Director Phase I Clinical Research, Director, Translational Oncology Program, Stanford University
                            Biography
                              Dr. Shivaani Kummar is a medical oncologist who specializes in early phase clinical drug development. She is Professor of Medicine and Director of the Phase I Clinical Research, Medical Oncology, and Translational Oncology Programs at Stanford University. She trained in Internal Medicine at Emory University in Atlanta, Georgia, and then pursued her fellowship training at the National Institutes of Health in Medical Oncology and Hematology. She then became Assistant Professor of Medicine at Yale Cancer Center, Yale University School of Medicine, where she developed in an interest in developmental therapeutics. She moved back to the National Cancer Institute (NCI), NIH, to build a clinical research program in novel cancer therapeutics and in 2011 became Head of Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, NCI. She subsequently moved to Stanford University in 2015 to create their early phase program in medical oncology. Her research interests focus on developing novel therapies for cancer, conducting pharmacokinetic and pharmacodynamic driven first-in-human trials. The clinical studies integrate genomics, imaging, and laboratory correlates into early phase trials. She serves on multiple national and international committees, and has widely published in high impact peer reviewed journals. She also serves as the Associate Division Chief for Medical Oncology.
                            • Marcel Perret-Gentil, DVM, MS
                              University Veterinarian & Director, Laboratory Animal Resources Center, University of Texas at San Antonio
                              Biography
                                Dr. Perret-Gentil currently serves as University Veterinarian and Director of the Laboratory Animal Resources Center at the University of Texas at San Antonio. He is also the Attending Veterinarian of the START Center for Cancer Care in San Antonio and Lester Smith Medical Research Institute. His educational background includes a Bachelor of Science in Animal Science, a Doctorate in Veterinary Medicine, a Residency and Master of Science in Comparative Medicine and a Fellowship in Experimental Minimally Invasive Surgery. Past employment has been with the United States Army, Ethicon Endo-Surgery, Merck, University of Florida and Texas Tech Health Sciences Center. As of the January of 2019, Dr. Perret-Gentil has published or contributed to 60 papers, articles and abstracts. He has presented 388 special presentations at various academic and research institutions, as well as national and international meetings. He serves as ad hoc Specialist for AAALAC International, and as consultant to the government, biotechnology industry and other institutions of higher education in the United States and abroad.
                              • Devendra Mistry, PhD
                                Senior Field Application Scientist, QIAGEN Advanced Genomics
                                Biography
                                  Devendra (Dev) received his PhD from University of California San Diego(UCSD) Biomedical Sciences graduate program and did postdoctoral studies under both academic and pharmaceutical settings. During his post-doctoral studies, he focused on cellular mechanisms regulating stem cells and cancer stem cells through next-gen sequencing data generation, analysis, interpretation and mining. Dev joined QIAGEN as a field application scientist in 2015. In the past 3 years, he has provided trainings to many pharma, biotech, academic and government investigators for different QIAGEN bioinformatics software. In addition, he has helped many of these users troubleshoot problems with their existing workflows and design new workflows.
                                • Elena Naumovska, PhD
                                  Scientist of Application Development, Mimetas - The Organ on a Chip Company
                                  Biography
                                    Elena Naumovska works as a R&D Scientist at Mimetas focusing in development of organotypic intestinal tissue models that will aide the toxicity evaluation and drug screening processes. She finished her undergraduate studies at the Sofia University "St. Kliment Ohridski", Bulgaria with a Major in Molecular Biology and master studies in Molecular and Cellular Biology at the Uppsala University, Sweden. Her work has been in different fields but mostly on interdisciplinary projects raging from fusogenic liposomes and cancer therapy, directed differentiation of embryonic (ES) and induced pluripotent stem cells (iPSC), cancer metabolomics and venous thrombosis. In her current position she is also a part of initial training network ITN-MIMIC and working to finish an industrial doctorate in connection to the University of Sheffield, UK later this year.
                                  • Lotta Raty
                                    Global Product Manager Cell Separation, Miltenyi Biotec
                                    Biography
                                      Lotta joined Miltenyi Biotec in 2016 as Global Product Manager for Cell Separation Instruments. In this role, she manages the development and marketing of instruments and automation solutions in the Cell Separation portfolio. Prior to joining Miltenyi, Lotta worked at PerkinElmer and Source BioScience in the molecular biology field in various sales and product specialist roles.
                                    • Khyati Shah, PhD
                                      Post Doctoral Research Scholar at University of California, San Francisco
                                      Biography
                                        Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in breast cancer. Currently, Khyati is the research fellow in Bandyopadhyay Lab since 2015. Her project involves investigation of the mechanism of resistance to targeted and immuno-therapy using systems biology approach. She has three-first author publications in the reputed peer-reviewed journals and 7 oral and 15 poster talks on the use of systemic genomics and proteomic approach to design rational combination therapy and to increase the durability of therapeutic response.
                                      • Martin Shaw
                                        Business Development Manager at AroCell AB
                                        Biography
                                          Martin Shaw has been involved in the development, production and promotion of novel biomarker and laboratory diagnostics for many years. His particular interest is using his technical and scientific skills and knowledge to link research to the customer's needs. In the field of laboratory diagnostics, he has been involved in the development and promotion of several ground-breaking products including the first commercial assays for neonatal TSH, anti-gliadin IgA and a range of inflammatory biomarkers. In the drug discovery industry, Martin has worked widely with novel cell and tissue injury biomarkers and their application to toxicology and drug discovery. Martin has participated in industry-wide consortia on the qualification on biomarkers for use in preclinical toxicology studies and phase I clinical trials Martin has published several review articles on the application of biomarkers in drug discovery and he has lectured at many conferences, including twice being guest speaker at the FDA. Currently he is working with a novel exciting biomarker of cell proliferation - The AroCell TK 210 ELISA kit that has great potential as a biomarker of cell proliferation in preclinical drug development and clinical trials.
                                        • Matthew Shipton, MS
                                          Chief Operating Officer, HµREL Corporation
                                          Biography
                                            Leading Hurel's commercial operations, Matthew K. Shipton brings to the Company a skill for implementing sales-driven business strategies, an extensive track record of meeting and surpassing targeted sales objectives, and a passion for translating customer needs into solutions that exceed customer expectations. In addition to his role of leading the Company's outreach and relationships with customers; serving as a customer advocate inside the Company, he works closely with Hurel's R&D team to articulate market needs and identify opportunities for new products. Over the past fourteen years, Mr. Shipton has amassed deep domain expertise in cell-based products and services. Immediately prior to joining Hurel, he served as the Central and Southern U.S. Regional Sales Manager for Bioreclamation IVT (formerly CelsisIVT), where he was responsible for leading regional revenue generation and new account growth. In that capacity Mr. Shipton organized and led multiple, dedicated strategic initiatives, including establishing the CelsisIVT partnership with the Research Institute for Liver Disease (RILD) in China, as well as consummating long-term supply agreements with a number of the major pharmaceutical companies. Prior to CelsisIVT, Mr. Shipton served as Director of North American Business Development for Cyprotex, PLC, a UK-based contract research organization ("CRO") specializing in preclinical drug discovery services. Before Cyprotex, he was Regional Sales Manager for CellzDirect, a Durham, NC based provider of primary hepatic cell-based products and services which in 2008 was acquired by Invitrogen (now Thermo Fisher). Mr. Shipton holds Master's and Bachelor's Degrees in Chemistry from, respectively, North Carolina State University and Youngstown State University.
                                          • Sarah Warren, PhD
                                            Director, Advanced Applications, NanoString
                                            Biography
                                              Sarah Warren is the director of advanced applications at NanoString and leads the early immuno-oncology research program. Prior to joining NanoString, she founded and ran Oncofactor Corp, a biotech focused on discovery of novel immune checkpoint inhibitors and development of therapeutics to block their activity. She has a PhD in immunology from the University of Washington and undergraduate degrees in biochemistry and English from Iowa State University.
                                            • Alex Zhavoronkov, PhD
                                              Founder and CEO, Insilico Medicine, Inc.
                                              Biography
                                                Dr. Zhavoronkov is the CEO of Insilico Medicine, a Rockville-based leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At Insilico he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties. He was the first to develop the deep-learned multi-modal predictors of age for drug and biomarker development. He set up the R&D centers in 6 countries including the United Kingdom, Korea, Russia, Hong Kong and Taiwan and launched multiple B2B and B2C research platforms including Young.AI. Prior to founding Insilico Medicine, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, the Biogerontology Research Foundation and YLabs.AI and established AgeNet.net competitions and Diversity.AI initiative. Since 2012 he published over 120 peer-reviewed research papers and books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Palgrave Macmillan, 2013). He is the co-organizer of the Annual Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum at the Basel Life/EMBO, one of Europe's largest industry events in drug discovery. Dr. Zhavoronkov holds two bachelor degrees from Queen's University, a master's in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
                                              FEB 27, 2019

                                              Drug Discovery 2019

                                              Our 2nd Annual Drug Discovery Virtual Event is now available On-Demand!  The event will remain open 6 months from the date of the live event.  The webinars will be available for unlimited on-demand viewing.

                                              Topic's for this years event included: 
                                              • Novel Strategies for Drug Discovery
                                                • Next-Generation In Silico Technologies
                                                • Second Harmonic Generation
                                                • Synthetic Antibodies/Molecularly Imprinted Polymers
                                                • Co-Culture Systems
                                              • Effective Tools for Drug Development
                                                • Artificial Intelligence
                                                • Well-designed In Vivo Studies
                                                • Aptamers
                                                • Combination Therapies to Overcome Resistance
                                                • Organ On A Chip
                                                • Pluripotent Stem Cells
                                              • Innovative Approaches in Clinical Trials
                                                • Basket Trials
                                                • Biomarkers

                                              Drug Discovery 2019 brought together industry leaders from around the world will join together and discuss the advancements, challenges and successes of discovery and development of new medications and therapies. Don't miss the opportunity to participate in this groundbreaking conference, which is absolutely free to all participants.

                                              Continuing Education
                                              LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 30 credits.


                                              Use #LRdrug to follow the conversation!


                                              Speakers

                                              Show Resources
                                              You May Also Like
                                              JUN 20, 2019 06:00 AM PDT
                                              C.E. CREDITS
                                              JUN 20, 2019 06:00 AM PDT
                                              LabRoots and the Precision Medicine Planning Committee are pleased to announce the 4th Annual Precision Medicine Virtual Event. Precision Medicine 2019, a two-day event held June 19-20, will...
                                              NOV 14, 2019 06:00 AM PST
                                              C.E. CREDITS
                                              NOV 14, 2019 06:00 AM PST
                                              Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2019 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
                                              AUG 22, 2019 06:00 AM PDT
                                              C.E. CREDITS
                                              AUG 22, 2019 06:00 AM PDT
                                              LabRoots is pleased to announce a new addition to our virtual conference line up for 2019, Forensics & Toxicology! The exciting field of Forensics/Toxicology is focused on a blend of biology...
                                              SEP 11, 2019 06:00 AM PDT
                                              C.E. CREDITS
                                              SEP 11, 2019 06:00 AM PDT
                                              LabRoots and the Microbiology Planning Committee is bringing the microbiology research community together at the 5th Annual Microbiology and Immunology Virtual Event! During the free, two-day...
                                              NOV 12, 2020 06:00 AM PST
                                              Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
                                              NOV 12, 2020 06:00 AM PST
                                              Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
                                              Ten years ago LabRoots launched a new system of learning for a global scientific audience. Now, the 2020 Clinical Diagnostics and Research Virtual Event will again bring together clinicians,...
                                              SEP 26, 2019 06:00 AM PDT
                                              C.E. CREDITS
                                              SEP 26, 2019 06:00 AM PDT
                                              LabRoots and the Cell Biology Planning Committee are please to announce the 3rd Annual Cell Biology Virtual Event, providing an opportunity to discuss recent discoveries in biological researc...
                                              Agenda
                                              • FEB 27, 2019 06:00 AM PST
                                                Speaker: Alex Zhavoronkov, PhD
                                              • FEB 27, 2019 06:00 AM PST
                                                Speaker: Devendra Mistry, PhD
                                                Sponsored By: QIAGEN
                                              • FEB 27, 2019 06:00 AM PST
                                                Speaker: Jay Campbell
                                              • FEB 27, 2019 07:30 AM PST
                                                Speaker: Frank McCormick, PhD
                                              • FEB 27, 2019 09:00 AM PST
                                                Speaker: Mark Hellewell, PhD
                                                Sponsored By: Roche Diagnostics
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: Khyati Shah, PhD
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: Matthew Flegal, BS, SRS
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: G. Thomas Caltagirone, PhD
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: Christopher Bunker, PhD
                                              • FEB 27, 2019 12:00 PM PST
                                                Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma
                                                Speaker: Sarah Warren, PhD
                                                Sponsored By: NanoString Technologies
                                              • FEB 27, 2019 12:00 PM PST
                                                Speaker: Adrian Kinkaid
                                              • FEB 27, 2019 12:00 PM PST
                                                Speaker: Martin Shaw
                                              • FEB 27, 2019 12:00 PM PST
                                                Speaker: Marcel Perret-Gentil, DVM, MS
                                              • FEB 27, 2019 01:30 PM PST
                                                Speaker: Matthew Shipton, MS
                                              • FEB 27, 2019 01:30 PM PST
                                                Speaker: Richard Eglen, PhD
                                              • FEB 27, 2019 01:30 PM PST
                                                Speaker: Bill Jackson, PhD
                                              • FEB 27, 2019 01:30 PM PST
                                                Sponsored By: Illumina
                                                Phillip Febbo, MD
                                                Chief Medical Officer, Illumina, Inc.
                                                Maude Champagne
                                                Clinical Oncology Marketing, Illumina, Inc.
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Lotta Raty
                                                Sponsored By: Miltenyi Biotec
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Shivaani Kummar, MD, FACP
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Elena Naumovska, PhD
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Jagath Reddy Junutula, PhD
                                              • Effective Tools for Drug Development
                                              • FEB 27, 2019 06:00 AM PST
                                                Speaker: Alex Zhavoronkov, PhD
                                              • FEB 27, 2019 06:00 AM PST
                                                Speaker: Devendra Mistry, PhD
                                                Sponsored By: QIAGEN
                                              • FEB 27, 2019 06:00 AM PST
                                                Speaker: Jay Campbell
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: Christopher Bunker, PhD
                                              • FEB 27, 2019 12:00 PM PST
                                                Evaluating Biomarkers for Response to Neoadjuvant Immune Checkpoint Blockade in Melanoma
                                                Speaker: Sarah Warren, PhD
                                                Sponsored By: NanoString Technologies
                                              • FEB 27, 2019 01:30 PM PST
                                                Speaker: Matthew Shipton, MS
                                              • FEB 27, 2019 01:30 PM PST
                                                Speaker: Richard Eglen, PhD
                                              • FEB 27, 2019 01:30 PM PST
                                                Sponsored By: Illumina
                                                Phillip Febbo, MD
                                                Chief Medical Officer, Illumina, Inc.
                                                Maude Champagne
                                                Clinical Oncology Marketing, Illumina, Inc.
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Lotta Raty
                                                Sponsored By: Miltenyi Biotec
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Elena Naumovska, PhD
                                              • Novel Strategies for Drug Discovery
                                              • FEB 27, 2019 07:30 AM PST
                                                Speaker: Frank McCormick, PhD
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: Matthew Flegal, BS, SRS
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: G. Thomas Caltagirone, PhD
                                              • FEB 27, 2019 12:00 PM PST
                                                Speaker: Adrian Kinkaid
                                              • FEB 27, 2019 12:00 PM PST
                                                Speaker: Marcel Perret-Gentil, DVM, MS
                                              • FEB 27, 2019 01:30 PM PST
                                                Speaker: Bill Jackson, PhD
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Jagath Reddy Junutula, PhD
                                              • Innovative Approaches in Clinical Trials
                                              • FEB 27, 2019 09:00 AM PST
                                                Speaker: Mark Hellewell, PhD
                                                Sponsored By: Roche Diagnostics
                                              • FEB 27, 2019 10:30 AM PST
                                                Speaker: Khyati Shah, PhD
                                              • FEB 27, 2019 12:00 PM PST
                                                Speaker: Martin Shaw
                                              • FEB 27, 2019 03:00 PM PST
                                                Speaker: Shivaani Kummar, MD, FACP
                                              Posters

                                              POSTER SUBMISSION GUIDELINES

                                              Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.


                                              SUBMIT YOUR ABSTRACT

                                              Enter the following information to this Submission Form:

                                              • Poster Title
                                              • Your Name
                                              • Your Institution
                                              • Your Email
                                              • Abstract describing the poster


                                              All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

                                              If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

                                              Questions? Email Posters@LabRoots.com

                                              LabRoots Policy

                                              Sponsored By

                                              For information on becoming a sponsor or exhibitor, please click here.


                                              C.E. Credits

                                              The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                                              Committee

                                              To download the Program Committee brochure here.


                                              • Annette Gilchrist

                                                An Associate Professor with Midwestern University, and adjunct faculty member at Northwestern University Dr. Annette Gilchrist has a PhD in Immunology from the University of Connecticut Health Center and a MS in Biochemistry from the University of Connecticut. Previously, she ...

                                                See more See less
                                              • Matthew Flegal

                                                Matt entered the research field over 20 years ago as a lab animal technician at the TSI/Mason contract research facility. He has worked at both contract facilities such as TSI and OREAD Biosafety as well in industry at Pharmacia, Pfizer, and Sanofi-Aventis. During that period he ...

                                                See more See less
                                              • Khyati Shah

                                                Khyati Shah received her Ph.D. in Molecular Pharmacology from the University of the Pacific, Stockton, California. Her graduate research was completed in the lab of Jesika Faridi, Ph.D. Her work focused on the investigation of the mechanism of Akt induced tamoxifen resistance in ...

                                                See more See less
                                              • Martin Shaw

                                                Between 1994-2015 he worked at EKF Diagnostics in Wales (formerly Argutus Medical) where he introduced and promoted a wide range of novel kidney and liver tests, including important biomarkers that are now being evaluated by the IMI (Innovative Medicines Initiative) and FDA as ...

                                                See more See less
                                              • Matthew Shipton

                                                Leading Novabiosis' primary cell business, Matthew brings to the Company a skill for implementing sales-driven business strategies, an extensive track record of meeting and surpassing targeted sales objectives, and a passion for translating customer needs into solutions that ...

                                                See more See less
                                              • Sid Topiol

                                                Sid Topiol is the founder and CSO of 3D-2drug LLC, a collaborative research organization incubating drug discovery projects. 3D-2drug is rooted in the deployment of protein structure/function information into novel and efficient drug discovery opportunities. Sid received his B.S ...

                                                See more See less
                                              Help

                                              General LabRoots Questions

                                              For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                              Contact us

                                              Virtual Events and Webinars

                                              Supported Configurations

                                              • Operating System Internet Explorer Firefox Chrome Safari
                                                Vista IE8+ FF10+ Chrome15+
                                                Windows 7 IE8+ FF10+ Chrome15+
                                                Windows 8 IE10 FF10+ Chrome15+
                                                Mac OS X   FF10+ Chrome15+ Safari5.1+
                                              • Cookie settings: session cookies enabled
                                              • Browser configuration must have JavaScript enabled
                                              • Adobe Flash player 10.2 or later

                                              To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                              Internet Connection

                                              • A minimum of 100Kbps is recommended for audio-only events
                                              • A minimum of 300Kbps is recommended for speaker on-video events

                                              Computer Equipment

                                              • Screen Resolution: Minimum 1024x768
                                              • Video Card: 65,000 colors minimum
                                              • Sound card and speakers (or headphones) for hearing webcast in full format
                                              • Audio Card: 16-bit minimum
                                              • RAM: 512MB of free RAM

                                              Firewall Protocol

                                              • HTTP on port 80 or HTTPS on port 443
                                              • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                              • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                              Work-At-Home Attendees

                                              • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                              For A Seamless Experience

                                              When using a mobile device, FREE Mobile Apps are available:

                                              - For viewing Webinars:

                                              - For viewing Virtual Events

                                              Attendee Guide

                                              • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                              Virtual Event and Webinar Support:

                                              Continuing Education (CME/CE) Support

                                              Loading Comments...
                                              Show Resources